Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 7.03 INR
Change Today -0.37 / -5.00%
Volume 5.0
VNMX On Other Exchanges
Symbol
Exchange
Mumbai
As of 6:00 AM 04/27/15 All times are local (Market data is delayed by at least 15 minutes).

venmax drugs & pharmaceutica (VNMX) Snapshot

Open
7.03
Previous Close
7.40
Day High
7.03
Day Low
7.03
52 Week High
02/24/15 - 8.79
52 Week Low
01/2/15 - 3.50
Market Cap
36.8M
Average Volume 10 Days
846.7
EPS TTM
-1.43
Shares Outstanding
5.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VENMAX DRUGS & PHARMACEUTICA (VNMX)

Related News

No related news articles were found.

venmax drugs & pharmaceutica (VNMX) Related Businessweek News

No Related Businessweek News Found

venmax drugs & pharmaceutica (VNMX) Details

Venmax Drugs & Pharmaceuticals Limited engages in the pharmaceutical business in India. It is involved in the manufacture and sale of bulk drugs intermediates. The company was formerly known as Yenkey Drugs and Pharmaceuticals Limited. Venmax Drugs & Pharmaceuticals Limited was incorporated in 1988 and is based in Hyderabad, India.

Founded in 1988

venmax drugs & pharmaceutica (VNMX) Top Compensated Officers

Chairman, Managing Director and Compliance Of...
Total Annual Compensation: 360.0K
Compensation as of Fiscal Year 2014.

venmax drugs & pharmaceutica (VNMX) Key Developments

Venmax Drugs And Pharmaceuticals Ltd, Board Meeting, Mar 31, 2015

Venmax Drugs And Pharmaceuticals Ltd, Board Meeting, Mar 31, 2015. Agenda: To appoint Gali Satya Venkata Divya Jyothi as woman director effective from March 31, 2015.

Venmax Drugs and Pharmaceuticals Ltd Announces Unaudited Standalone Earnings Results for the Third Quarter and Nine Months Ended December 31, 2014

Venmax Drugs And Pharmaceuticals Ltd. announced unaudited standalone earnings results for the third quarter and nine months ended December 31, 2014. For the quarter, the company reported net sales of INR 1.593 million compared with INR 0.989 million for the same period a year ago. Loss from operation before other income, finance cost and exceptional items was INR 0.039 million compared with profit from operation before other income, finance cost and exceptional items of INR 0.043 million for the same period a year ago. Loss from ordinary activities before tax was INR 0.039 million compared with profit from ordinary activities before tax of INR 0.043 million for the same period a year ago. Net loss was INR 0.039 million compared with net profit of INR 0.043 million for the same period a year ago. For the nine months, the company reported net sales of INR 20.613 million compared with INR 4.099 million for the same period a year ago. Profit from operation before other income, finance cost and exceptional items was INR 0.088 million compared with INR 0.119 million for the same period a year ago. Profit from ordinary activities before tax was INR 0.088 million compared with INR 0.119 million for the same period a year ago. Net profit was INR 0.088 million compared with INR 0.119 million for the same period a year ago.

Venmax Drugs And Pharmaceuticals Ltd, Board Meeting, Feb 09, 2015

Venmax Drugs And Pharmaceuticals Ltd, Board Meeting, Feb 09, 2015. Agenda: To consider unaudited standalone earnings results for the third quarter and nine months ended December 31, 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VNMX:IN 7.03 INR -0.37

VNMX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VNMX.
View Industry Companies
 

Industry Analysis

VNMX

Industry Average

Valuation VNMX Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VENMAX DRUGS & PHARMACEUTICA, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.